Injectable testosterone ester
Testosterone Propionate
Testosterone Propionate after one dose: 50% at ~19 h, 25% at 38 h, 12.5% at 57 h.
Drawn from the half-life in the app's model, ~19 h. The model's figures
- Compound
- Testosterone Propionate
- Symbol
- TP
- Family
- Testosterone esters
- Parts
- 13
- References
- 17
- Checked
- Last reviewed . Sources are listed below.
Overview
Kicman wrote in the British Journal of Pharmacology in 2008 that parenteral anabolic steroid preparations usually have the 17β-hydroxyl group esterified with an acid moiety, and the list of testosterone esters given there includes propionate.3
A DailyMed search by the drug name testosterone propionate, run on 16 November 2026, returned no label for a single-ingredient injection for people; the one label it returned is for Synovex H, a subcutaneous implant for beef heifers that contains testosterone propionate and estradiol benzoate.16,17
Testosterone propionate also appears as one of four esters in Sustanon 250, and the UK label for that product lists 30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate in each 1 mL ampoule.4
The figures row at the top and the “Strong evidence” tag are the app's own: no cited source reports the 95% bioavailability, the time to peak, subcutaneous use or a repeated dose of 150 to 500 mg per week for testosterone propionate, and none grades the evidence for it.
How it works
Sources in this part
Kicman wrote that once an injected ester is in the circulation, “hydrolysis rapidly occurs by the action of blood esterases to yield the active compound”.3
He added that the duration of action of the esters depends on the rate of absorption from the site of administration, which depends on the chain length of the acid moiety and also the formulation, and that “in general, the longer the chain length, the more slowly the preparation is released into circulation”.3
Turza and colleagues wrote in Materials in 2022 that the testosterone base “has a short half-life of roughly a few hours” and is therefore often esterified.1
In the 1976 study of Nieschlag and colleagues, LH levels were suppressed for the same periods in which plasma testosterone was elevated after intramuscular testosterone esters, in normal and hypogonadal men.2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~19 h
- Bioavailability
- 95%
- Typical dose
- 150–500 mg/week
- Route
- IM / SubQ
- Time to peak
- ~24 h
The Milligram app uses a half-life of about 19 hours for testosterone propionate, a time to peak of about 24 hours and a bioavailability of 95%.
Turza and colleagues wrote that esterified forms of testosterone have half-lives “from around less than 1 day for testosterone acetate, 1 day for propionate, 2.5 days for phenylpropionate, and up to 3.1 days for testosterone isocaproate”.1
They cite a 2015 paper on detecting testosterone esters in blood for those figures, and the cited summary of that paper gives no half-lives.1,9
The app lists a duration of about 48 hours; the 1976 study of Nieschlag and colleagues reports 1 day after 25 mg and 2 days after 50 mg, and its cited summary reports no half-life, time to peak or number of men.2
| Measure | Figure | Source and note |
|---|---|---|
| Half-life, the app | ~19 hours | The app's figure; the cited sources report no measured half-life for propionate alone. |
| Half-life, Turza and colleagues, 2022 | 1 day | A statement in the background of a structural study, citing a 2015 detection paper.1 |
| Time to peak, the app | ~24 hours | The app's figure; the cited sources report no time to peak for propionate alone. |
| Bioavailability, the app | 95% | The app's figure; none of the cited sources gives a bioavailability percentage for testosterone propionate. |
| Time above lower physiological limit, Nieschlag and colleagues, 1976 | 1 day after 25 mg; 2 days after 50 mg | Intramuscular testosterone propionate in normal and hypogonadal men; number of men not given in the cited summary.2 |
| Peak and return, Sustanon 250 label | About 70 nmol/l total plasma testosterone at 24 to 48 hours; about 21 days to the lower limit of the normal range in males | Single dose of a mixture that includes 30 mg testosterone propionate per mL; not propionate alone.4 |
Level curve between doses
The chart below draws a one-compartment model with the app's half-life of 19 hours and time to peak of about 24 hours; it is an illustration and not a measured or predicted level for any person.
The cited sources report two dosing intervals for injected testosterone propionate on its own, twice a week in Ma and colleagues and every 3 weeks in Baghel and colleagues, 2025; the chart draws only the 3-week interval, its default dose is 50 mg, the larger dose in the 1976 study, and its slider runs from 10 to 100 mg, the largest fixed dose of propionate alone in the cited sources (Ma and colleagues), and is not tied to the app's 150 to 500 mg per week.5,8,2
Level over 4 weeks
Level, as a share of the peak after one 50 mg dose
As studied: every 21 days8.
An illustration from a pharmacokinetic model using a half-life of 19 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Nieschlag and colleagues, 19762 | Plasma testosterone and LH after intramuscular esters and testosterone suppositories; enanthate also tested | Normal and hypogonadal men; number not given in the cited summary | 25 mg or 50 mg propionate; 250 mg enanthate | Testosterone above the lower physiological limit for 1 day after 25 mg and 2 days after 50 mg propionate, 14 days after 250 mg enanthate; LH suppressed for the corresponding periods. |
| Ma and colleagues, 20205 | Retrospective analysis at one hospital, 2009 to 2019; propionate group against a control group without it | 61 patients with sepsis in intensive care (groups of 31 and 30 by the mortality denominators) | 100 mg deep intramuscular twice a week (twice in total), added to routine treatment | After treatment: albumin 39.87±1.98 vs 26.25±4.13 g/L, APACHE II 13.71±2.13 vs 23.23±2.52, mechanical ventilation 3.00±1.85 vs 7.00±2.50 days (all P < 0.05); 28-day all-cause mortality 3.2% (1/31) vs 13.3% (4/30), P > 0.05. |
| Paiva and colleagues, 20166 | Randomized, double-blind trial of topical preparations before hypospadias surgery | 69 children with hypospadias: 28 given 1% testosterone propionate, 17 placebo cream, 24 0.01% estradiol | Applied to the entire penis twice daily for 30 days; checks at 30 and 90 days | After 30 days penile diameter, length and glans diameter increased in the testosterone group (p < 0.05; comparator not stated in the cited summary); no significant variations in serum hormonal levels. |
| de Andrade and colleagues, 20177 | Randomized, double-blind, placebo-controlled trial of topical propionate | 35 boys with hypospadias aged 6 months to 9 years analyzed: 17 propionate, 18 placebo | 1% ointment twice a day for 30 days; checks at 30 and 90 days | At 30 days left ventricular mass index 59.21 ± 11.91 vs 55.12 ± 8.29 g/m2 (p = 0.244); serum testosterone 12 (7-80) vs 5 (5-7) ng/dL (p = 0.018); systolic blood pressure 83.82 ± 7.18 vs 77.5 ± 6.69 mmHg (p = 0.010). |
| Baghel and colleagues, 20258 | Single-group report before hypospadias surgery; no comparison group described in the cited summary | 40 people with hypospadias | 2 mg per kg deep intramuscular, three doses 3 weeks apart | Mean increases of 0.94 ± 0.14 in diameter at the base of the penis, 1.03 ± 0.48 in glans diameter and 1.09 ± 0.25 in penile length (units not given), all P < 0.001. |
Studies of mixtures that contain propionate
Ahmad, Chalapathi and Büyükgebiz and colleagues gave propionate only as part of a mixture, so their results are not read as results of propionate alone.10,11,12
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Ahmad and colleagues, 201110 | Single-group study before hypospadias repair; no comparison group described in the cited summary | 23 patients with hypospadias | Oily solution with 25 mg propionate and 110 mg enanthate per mL, 2 mg/kg deep intramuscularly 4, 3 and 2 weeks before surgery | Mean increase 1.35±0.40 cm in penile length (P<0.001); serum testosterone within the normal range for age; fine pubic hair. |
| Chalapathi and colleagues, 200311 | Controlled clinical trial; patients recruited alternately to topical or intramuscular use of the same mixture | 26 patients with hypospadias and a small penis, 13 in each group | Testoviron: topical 2 mg/kg a week for 3 weeks (group A) or weekly intramuscular injection for 3 weeks (group B) | Penile length from an average 2.0 and 1.8 cm to 3.18 and 3.11 cm in groups A and B (P <.01 against pretherapy in both); significant penile enlargement in 60% of group A and 75% of group B, growth of at least 50% in 7 patients in each group; no significant difference between routes; in group A serum testosterone above the normal range in 2 patients, pubic hair in 2 patients and “significant reversible side effects”. |
| Büyükgebiz, 199512 | Clinical trial, no comparison group described in the cited summary, followed for 2 years | 13 boys with constitutional delayed puberty, mean age 14.9 ± 0.6 years | Propionate, phenylpropionate and isocaproate combined; 200 mg testosterone intramuscularly 4 times at 3-week intervals | All 13 entered puberty after the last dose; growth rate rose from 4.5 ± 0.5 to 8.4 ± 1.6 cm/year after 2 years, while height for bone age SD score did not alter significantly (-1.1 to -1.3) and predicted height was 173.5 ± 6.6 cm before and 173.3 ± 4.9 cm after; the author concludes the combination is “a safe and effective treatment for prepubertal boys with CDP”. |
Deeper analysis: the 1976 plasma testosterone study
Nieschlag, Cüppers, Wiegelmann and Wickings reported the study in Hormone Research in 1976, measuring plasma testosterone and LH in normal and hypogonadal men after intramuscular testosterone esters and after free testosterone suppositories (3 x 20 mg for 5 days), which maintained elevated testosterone and suppressed LH.2
The cited summary gives no number of men, time to peak, half-life, adverse events, funder, author tie to a sponsor or limitations.2
Deeper analysis: the 2020 analysis of patients with sepsis
Ma, Zhang, Shi and colleagues at Weinan Central Hospital, Shaanxi, China, reported the analysis in Zhonghua Wei Zhong Bing Ji Jiu Yi Xue in 2020: the data of 61 sepsis patients admitted to intensive care from June 2009 to October 2019 were “retrospectively analyzed”, and on top of routine treatment the observation group was given 100 mg of testosterone propionate by deep intramuscular injection twice a week (twice in total) while the control group was not.5
Baseline data did not differ between the groups, and after treatment the observation group had higher testosterone (3.69±2.38 vs 2.85±0.90 μg/L) and lower SOFA (4.45±1.57 vs 9.97±2.65), ICU hospitalization time (12.36±4.37 vs 14.03±3.86 days) and total hospitalization expenses (10.14±3.22 vs 12.10±3.91 ten thousand Yuan), all P < 0.05.5
The authors concluded that “Testosterone propionate injection can increase albumin level, shorten the time of mechanical ventilation, and improve the condition and prognosis of patients with sepsis.”5
The cited summary describes a retrospective comparison with no randomization stated and reports no adverse events; 28-day all-cause mortality is reported as an outcome and was not significantly different (3.2% (1/31) vs 13.3% (4/30)). It states no limitations, funder or author tie to a sponsor.5
Deeper analysis: the topical propionate trials in children with hypospadias
Paiva and colleagues at the Federal University of Juiz de Fora, Brazil, reported a randomized, double-blind controlled trial in the Journal of Pediatric Urology in 2016, and de Andrade and colleagues at the same university reported a second one in 2017.6,7
In Paiva and colleagues, 69 children were randomly divided into a placebo cream group of 17, a 1% testosterone propionate group of 28 and a 0.01% estradiol group of 24, and after 30 days penile diameter, penile length and glans diameter had increased in the testosterone group (p < 0.05), while the width of the urethral plate and the distance from the meatus to the tip increased not significantly; the cited summary does not say whether the p value is against placebo or baseline and gives no magnitudes or 90-day measurements.6
In de Andrade and colleagues, whose aim was to evaluate the effect of topical testosterone on left ventricular mass index, 35 children were analyzed (17 and 18) and the index did not differ between groups at 30 days (p = 0.244) or 90 days (61.13 ± 11.69 vs 62.84 ± 35.99 g/m2, p = 0.852), while systolic blood pressure was higher with testosterone at 30 days and similar between groups at 90 days (p = 0.588).7
The authors concluded that topical testosterone “can be considered safe in the preoperative period of children with hypospadias with no risk of left ventricular hypertrophy”. The summary of de Andrade and colleagues reports 17 and 18 children and a 90-day control standard deviation of ±35.99 g/m2, and the cited summaries of both trials state no funder, author tie to a sponsor or limitations.7,6
Paiva and colleagues report “No significant variations were seen in serum hormonal levels” and “No significant and persistent hormonal changes were observed”, without the cited summary saying which hormones were measured. De Andrade and colleagues report serum testosterone of 12 (7-80) vs 5 (5-7) ng/dL at 30 days (p = 0.018) and 10 (5-11) vs 5 (4-5) ng/dL at 90 days (p = 0.155).6,7
Deeper analysis: the 2025 series of intramuscular injections
Baghel, Dawar, Mandloi, Rawat and Rawat, at Dr. Laxmi Narayan Pandey Government Medical College in Ratlam, Madhya Pradesh, India, reported the series in the Journal of Pharmacy and Bioallied Sciences in 2025: 40 people with hypospadias were given testosterone propionate injection at 2 mg per kg body weight, deep intramuscularly, in three doses 3 weeks apart before reconstructive surgery, and the mean increases were 0.94 ± 0.14 in diameter at the base of the penis, 1.03 ± 0.48 in glans diameter and 1.09 ± 0.25 in penile length, each P < 0.001.8
The authors concluded that injection leads to an increase in those measures “without any notable associated severe side effects”, noting “minor side effects” of aggressiveness, acne and fine pubic hair development; the record states “There are no conflicts of interest” and names no funder, units, comparison group or limitations.8
Doses reported in studies and on labels
| Source | Who | Dose reported | Route |
|---|---|---|---|
| Nieschlag and colleagues, 19762 | Normal and hypogonadal men | 25 mg and 50 mg testosterone propionate; how often they were given is not stated in the cited summary | Intramuscular |
| Ma and colleagues, 20205 | Patients with sepsis | 100 mg twice a week (twice in total) | Deep intramuscular |
| Baghel and colleagues, 20258 | People with hypospadias before surgery | 2 mg per kg body weight, three doses 3 weeks apart | Deep intramuscular |
| Paiva and colleagues, 20166 | Children with hypospadias | 1% preparation twice daily for 30 days | Topical, on the entire penis |
| de Andrade and colleagues, 20177 | Boys aged 6 months to 9 years with hypospadias | 1% ointment twice a day for 30 days | Topical |
| Sustanon 250 UK label4 | Adults with male hypogonadism (testosterone replacement therapy, when testosterone deficiency has been confirmed by clinical features and biochemical tests), or as supportive therapy for female-to-male transsexuals; the label states the dose is adjusted to the response of the individual patient | 1 mL (30 mg testosterone propionate with three other esters) usually per 3 weeks | Deep intramuscular |
The app's typical dose range is 150 to 500 mg per week and its routes are IM and SubQ.
No cited source reports 150 to 500 mg per week as a repeated dose or in healthy or hypogonadal adults; Ma and colleagues gave two injections of 100 mg (200 mg in total) to patients with sepsis in intensive care, and the 25 mg and 50 mg doses in Nieschlag and colleagues had no stated frequency. No cited source reports subcutaneous testosterone propionate.5,2
Side effects reported
Studies of propionate on its own
In Paiva and colleagues the most frequent side effects were pubic hair and darkening of genital skin, mainly with testosterone, described as transient and gone after 90 days, and Baghel and colleagues list minor side effects of aggressiveness, acne and fine pubic hair development.6,8
In de Andrade and colleagues systolic blood pressure was higher with testosterone than with placebo at 30 days (83.82 ± 7.18 vs 77.5 ± 6.69 mmHg, p = 0.010) and similar between groups at 90 days (p = 0.588), which the authors describe as a return to basal levels.7
The cited summary of Nieschlag and colleagues reports no adverse events, and neither does that of Ma and colleagues, whose 28-day all-cause mortality figures, 3.2% (1/31) with propionate against 13.3% (4/30) without, P > 0.05, are an outcome.2,5
Studies of mixtures that contain propionate
Ahmad and colleagues report “Minimal side effects” in the form of fine pubic hair development, and Chalapathi and colleagues report that serum testosterone crossed the normal range in 2 of 13 children treated topically, with “significant reversible side effects”.10,11
What the Sustanon 250 label lists
The UK label for Sustanon 250 states that its adverse reactions have been associated with androgen therapy in general. It rates weight increased as common and pulmonary oil microembolism as rare, and polycythaemia, fluid retention, hypertension, acne, gynaecomastia, oligospermia, depression, abnormal hepatic function and prostatic cancer (progression of a sub-clinical cancer) as not known, meaning the frequency cannot be estimated from the available data; its laboratory group (lipids abnormal, PSA increased, increased haematocrit) carries both “Not known” and “Common”.4
It lists contraindications of pregnancy, known or suspected carcinoma of the prostate or breast, breast-feeding, and hypersensitivity including allergy to peanuts or soya, and states that “Abuse of testosterone and other anabolic androgenic steroids can lead to serious adverse reactions including: cardiovascular (with fatal outcomes in some cases), hepatic and/or psychiatric events.”4
The label states that “Safety and efficacy have not been adequately determined in children and adolescents”; for prepubertal children using androgens it lists “precocious sexual development, an increased frequency of erections, phallic enlargement and premature epiphyseal closure”, and it states that “side effects cannot be quickly reversed by discontinuing medication”. The list above is partial: the label also lists priapism, benign prostatic hyperplasia, nausea, myalgia, pruritus, ejaculation disorder and libido changes.4
Bloodwork and markers
Sources in this part
The Milligram app lists total testosterone, free testosterone, estradiol, hematocrit, lipids and PSA as its markers for testosterone propionate.
The UK label for Sustanon 250 lists testosterone level at baseline and at regular intervals, prostate examination with PSA, haematocrit and haemoglobin, and, in long-term therapy, liver function tests and lipid profile among the parameters it names for monitoring. The label does not name free testosterone or estradiol among them.4
Regulatory and anti-doping status
The World Anti-Doping Agency's 2026 Prohibited List places anabolic agents in S1, prohibited at all times in and out of competition, and anabolic androgenic steroids in S1.1 “When administered exogenously, including but not limited to”, with testosterone in that list.13
The list text reads “and other substances with a similar chemical structure or similar biological effect(s) including their esters” and does not name propionate.13
21 CFR 1308.13(f), a US federal regulation, lists testosterone (17β-hydroxyandrost-4-en-3-one) among the Schedule III anabolic steroids, “including its salts, esters and ethers”, under the lead-in “Unless specifically excepted or unless listed in another schedule”, and the regulation text does not name propionate.14
The Sustanon 250 label states that the product can interfere with anti-doping testing.4
Solheim and colleagues, in Drug Testing and Analysis in 2022, gave men two intramuscular injections of Sustanon 250 (n = 9) or placebo (n = 10) and report detection of the esters in dried blood spots in all subjects for at least 5 days, with a window of up to 14 days for three of the esters (the cited summary does not say which three); the work was supported by Anti Doping Denmark, the Innovation Fund and the Partnership for Clean Competition, and one author affiliation is Anti-Doping Denmark.15
What is not known
The cited sources report no measured half-life, time to peak or bioavailability for testosterone propionate on its own, so the app's figures of about 19 hours, about 24 hours and 95% are not matched by a cited source.
None of the single-ester studies cited gives repeated weekly doses of 150 to 500 mg over several weeks.5,6,7,8
Results from the mixtures, including Sustanon 250 and Testoviron, are not read as results of propionate, and the Sustanon 250 label's pharmacokinetic figures describe a four-ester product.4
The sources cited include one UK label, a US regulation and the WADA list; labels from other countries were not among them.
Frequently asked questions
What is the half-life of testosterone propionate?
The app uses a half-life of about 19 hours for testosterone propionate. Turza and colleagues, in 2022, state a half-life of 1 day for propionate.1 The cited sources report no measured half-life for testosterone propionate on its own.
How long does testosterone propionate last?
In a 1976 study, plasma testosterone stayed above the lower physiological limit for 1 day after 25 mg and for 2 days after 50 mg of intramuscular testosterone propionate.2 The app lists a duration of about 48 hours.
How long does testosterone propionate take to peak?
The app uses a time to peak of about 24 hours. The cited sources report no time to peak for testosterone propionate on its own. The UK label for Sustanon 250, a four-ester mixture, states peak total plasma testosterone approximately 24 to 48 hours after a single dose.4
What is the bioavailability of testosterone propionate?
The app uses a bioavailability of 95%. None of the cited sources gives a bioavailability percentage for testosterone propionate.
Is testosterone propionate banned by WADA?
The World Anti-Doping Agency's 2026 Prohibited List does not name propionate. It prohibits anabolic androgenic steroids at all times, in and out of competition, lists testosterone in S1.1 and ends the list with “other substances with a similar chemical structure or similar biological effect(s) including their esters”; the cited text does not say whether that wording covers propionate.13
Is testosterone propionate a controlled substance?
In US federal regulation, 21 CFR 1308.13(f) places testosterone “including its salts, esters and ethers” in Schedule III, under the lead-in “Unless specifically excepted or unless listed in another schedule”.14 The regulation text does not name propionate, and rules outside the United States were not among the cited sources.
Is testosterone propionate in Sustanon 250?
Yes, the UK label for Sustanon 250 lists 30 mg testosterone propionate in each 1 mL ampoule, with 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate.4
Is there a US label for testosterone propionate injection?
What side effects were reported in studies of testosterone propionate?
Studies of testosterone propionate on its own in people with hypospadias, by topical use or injection, report pubic hair, darkening of genital skin, aggressiveness, acne, and a higher systolic blood pressure than placebo at 30 days that the authors describe as back to basal levels at 90 days.6,8,7 The cited summaries of Nieschlag and colleagues and of Ma and colleagues report no adverse events, and the Sustanon 250 label lists many more reactions for its four-ester product.2,5,4
Guides, tools and comparisons
References
- Turza A, Popescu V, Mare L, Borodi G. Structural Aspects and Intermolecular Energy for Some Short Testosterone Esters. Materials (Basel) 2022. PMC9611952
- Nieschlag E, Cüppers HJ, Wiegelmann W, Wickings EJ. Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 1976. PMID 1002121
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008. PMC2439524
- Aspen Pharma Trading Limited. Sustanon 250, 250mg/ml solution for injection. Summary of Product Characteristics, emc, revised December 2025. emc SmPC
- Ma L, et al. [Effect of testosterone propionate on condition and prognosis of sepsis patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020. PMID 33541496
- Paiva KC, et al. Biometry of the hypospadic penis after hormone therapy (testosterone and estrogen): A randomized, double-blind controlled trial. J Pediatr Urol 2016. PMID 27321554
- de Andrade EC, et al. Echocardiographic evaluation of left ventricular mass index in children with hypospadias after hormonal stimulation with topical testosterone: A randomized controlled trial. J Pediatr Urol 2017. PMID 28434633
- Baghel PS, et al. Assessing the Efficacy of Parental Testosterone Therapy in the Penis Size Before Hypospadias Surgery. J Pharm Bioallied Sci 2025. PMID 40510958
- Forsdahl G, et al. Detection of testosterone esters in blood. Drug Test Anal 2015. PMID 26695486
- Ahmad R, Chana RS, Ali SM, Khan S. Role of parenteral testosterone in hypospadias: A study from a teaching hospital in India. Urol Ann 2011. PMID 21976926
- Chalapathi G, et al. Testosterone therapy in microphallic hypospadias: topical or parenteral? J Pediatr Surg 2003. PMID 12596107
- Büyükgebiz A. Treatment of constitutional delayed puberty with a combination of testosterone esters. Horm Res 1995. PMID 8719438
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force 1 January 2026. WADA list 2026
- US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations. eCFR 1308.13
- Solheim SA, et al. Stability and detectability of testosterone esters in dried blood spots after intramuscular injections. Drug Test Anal 2022. PMID 33733610
- US National Library of Medicine. DailyMed, drug name search for testosterone propionate (spls service), run 16 November 2026; database published 13 November 2026. DailyMed search
- Zoetis Inc. Synovex H (testosterone propionate and estradiol benzoate) implants, label. DailyMed set id 5cdef530-023e-4d34-8e97-77f143b0068f. DailyMed Synovex H